ASCO 2023: Adjuvant Ribociclib Plus Endocrine Therapy in Early-Stage Breast Cancer
Posted: 06/13/2023 | By: Chase Doyle

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Slamon et al presented results from the phase III NATALEE trial, which evaluated adjuvant ribociclib plus endocrine therapy in a broad population of patients with early breast cancer who were at risk for recurrence (Abstract LBA500).

Question 1 of 5

What was the primary endpoint of the phase III NATALEE trial?

Choose 1